Bausch & Lomb
This article was originally published in The Tan Sheet
U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...
You may also be interested in...
If all those at risk for developing age-related macular degeneration received dietary supplements like Bausch & Lomb's Ocuvite PreserVision, more than 300,000 of them would avoid advanced AMD and any associated vision loss during the next five years, according to a study in the November Archives of Ophthalmology.
Bausch & Lomb plans to boost top line growth in its lens care category with the introduction of a new "first of its kind" lens solution next year
SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.